Analysts' recommendations: Alzinova AB

24/06	RX Securities reiterates buy on Alzinova after letter of intent with Fujirebio	FW
08/04	RX Securities sees potential upside for Alzinova from Alzheimer's diagnostic collaboration	FW
26/03	DNB Carnegie sees reduced financing risk for Alzinova, but partnership remains critical	FW
06/10/25	Alzinova gets fast track designation from US FDA	RE
06/10/25	Alzinova's Alzheimer's Disease Vaccine Candidate Gets Fast-track Designation from US FDA	MT

More recommendations

Managers and Directors: Alzinova AB

Manager	Title	Age	Since
Tord Labuda CEO	Chief Executive Officer	59	01/10/2024
Anders Sandberg COO	Chief Operating Officer	54	17/08/2011
Erik Kullgren DFI	Director of Finance/CFO	57	27/03/2024

Director	Title	Age	Since
Clas Malmeström BRD	Director/Board Member	61	01/09/2015
Anders Waas BRD	Director/Board Member	69	01/01/2018
Carol Routledge BRD	Director/Board Member	-	01/01/2018

More insiders

Other Biotechnology & Medical Research

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ALZINOVA AB	+14.17%	+38.10%	-26.68%	-66.18%	24.65M
LONZA GROUP AG	-1.40%	+2.59%	-1.71%	+11.28%	48.53B
REVOLUTION MEDICINES, INC.	-2.41%	-0.90%	+403.17%	+614.40%	39.87B
IQVIA HOLDINGS INC.	-1.16%	+12.96%	+26.45%	+5.03%	38.68B
BEONE MEDICINES AG	-1.88%	-3.03%	+4.94%	+47.52%	35.13B
CELLTRION, INC.	-1.74%	+5.12%	+9.58%	+46.02%	29.79B
ASCENDIS PHARMA A/S	-2.85%	-3.92%	-	-	16.08B
MEDPACE HOLDINGS, INC.	-0.21%	-4.04%	+35.09%	+127.95%	16.11B
EUROFINS SCIENTIFIC SE	-0.64%	+2.65%	+1.25%	+8.92%	13.61B
ICON PUBLIC LIMITED COMPANY	-1.19%	-1.32%	-3.32%	-34.94%	12.62B
Average	+0.07%	+4.76%	+49.86%	+84.44%	25.04B
Weighted average by Cap.	-1.59%	+2.04%	+76.85%	+128.08%

See all sector performances

Alzinova AB is a Sweden-based company, which is primarily involved in the biotechnology industry. The Company is engaged in the discovery and development of therapeutics for the treatment of Alzheimerâ€™s disease. The Company focuses on development of a specific oligomer-directed vaccine (ALZ-101), as well as on the development of diagnostics based on a monoclonal antibody (ALZ-201). Both products are specifically directed towards the form of oligomeric AÎ² that damages brain synapses.

Employees

Sector

Biotechnology & Medical Research

Calendar

20/08 Earnings release - Q2 2026

More about the company

Quotes

Date	Price	Change	Volume
31/07/26	SEK 1.160	+14.17%	7,413,903
30/07/26	SEK 1.016	+3.89%	2,344,913
29/07/26	SEK 0.9780	-5.05%	5,308,647
28/07/26	SEK 1.030	-2.83%	6,080,675
27/07/26	SEK 1.060	+26.19%	8,929,009

Delayed Quote Nasdaq Stockholm

More quotes

Income Statement and Estimates

More financial data

EPS Estimates

Revisions to estimates

Annual profits - Rate of surprise

Company calendar

Select your edition

All financial news and data tailored to specific country editions

NORTH AMERICA

United-States

Canada

Market Closed - Nasdaq Stockholm Other stock markets 02:00:00 01/08/26 am AEST			5-day change	1st Jan Change
1.160 ^SEK	+14.17%		+38.10%	+39.93%

Market Cap	235M 24.65M 21.42M 19.94M 18.31M 34.58M 2.35B 35.11M 92.26M 1.17B 92.56M 90.53M 3.93B	P/E 2026 *	-4.3x	P/E 2027 *	-3.05x
Enterprise Value	219M 22.97M 19.97M 18.58M 17.06M 32.22M 2.19B 32.72M 85.98M 1.09B 86.26M 84.37M 3.66B	EV / Sales 2026 *	6.99x	EV / Sales 2027 *	-
Free-Float	82.23%	Yield 2026 *	-	Yield 2027 *	-

25/06	Alzinova AB and Fujirebio Enter Letter of Intent for Potential Commercialization of Blood-Based Alzheimer?S Diagnostic Test	CI
24/06	Alzinova Inks Nonbinding Deal with Fujirebio for Potential Alzheimer's Blood-based Diagnostic Test	MT
24/06	RX Securities reiterates buy on Alzinova after letter of intent with Fujirebio	FW
24/06	Alzinova signs non-binding letter of intent with Fujirebio on Alzheimer's diagnostics	FW
12/06	Alzinova raises SEK15.3m from warrants: underwriting not required	FW
09/06	Alzinova raises SEK 15.2 million before issuance costs	FW
26/05	Calendar Tuesday May 26	FW
25/05	Calendar Tuesday May 26	FW
21/05	Alzinova secures 80 percent of TO4 warrants	FW
20/05	Alzinova phase 1b results published in scientific journal	FW
20/05	Alzinova AB Publishes Clinical Results with ALZ-101 in Alzheimer?s Research & Therapy	CI
13/05	Alzinova AB Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
13/05	Alzinova Q1 loss after financial items SEK 6 mln	RE

07/07	BioVal™ analysis of Alzinova's ALZ-101 – rNPV of SEK 7.1B	AQ
25/06	Alzinova: Newsflow update – diagnostic optionality and TO4 proceeds	AQ
24/06	Alzinova signs Letter of Intent with Fujirebio regarding potential commercialization of blood-based Alzheimer’s diagnostic test	AQ
12/06	Warrants of series TO4 were exercised to approximately 94.2 percent and the Company will receive approximately 15.3 million	AQ
09/06	Alzinova announces preliminary outcome of the exercise of warrants of series TO4	AQ

1 day	+14.17%
1 week	+38.10%
1 month	+133.87%
3 months	+162.15%
6 months	+48.72%
Current year	+39.93%

Alzinova AB Stock

Stocks

ALZ

SE0007413455

Biotechnology & Medical Research

Valuation: Alzinova AB

Chart: Alzinova AB

Latest news : Alzinova AB

Analysts' recommendations: Alzinova AB

Press Releases: Alzinova AB

Quotes and Performance

Course Extremes

Managers and Directors: Alzinova AB

Other Biotechnology & Medical Research

Financials

Company Profile

Quotes

Income Statement and Estimates

Annual profits - Rate of surprise

1 week	0.79	1.2
1 month	0.48	1.61
Current year	0.38	1.61
1 year	0.38	2.28
3 years	0.38	4.62
5 years	0.38	8.7
10 years	0.38	44.9

	2026 *	2027 *
Net sales	31.35M 3.29M 2.86M 2.66M 2.44M 4.61M 314M 4.68M 12.3M 156M 12.34M 12.07M 524M	-
Net income	-3.2M -336K -292K -271K -249K -471K -32.03M -478K -1.26M -15.95M -1.26M -1.23M -53.47M	-50.35M -5.28M -4.59M -4.27M -3.92M -7.41M -504M -7.52M -19.76M -251M -19.83M -19.39M -841M
Net Debt	-16M -1.68M -1.46M -1.36M -1.25M -2.35M -160M -2.39M -6.28M -79.73M -6.3M -6.16M -267M	-19M -1.99M -1.73M -1.61M -1.48M -2.79M -190M -2.84M -7.46M -94.67M -7.48M -7.32M -317M